テルモは11日、血液製剤の原料となる血漿（けっしょう）の採取装置が米食品医薬品局（FDA）の認証を取得したと発表した。2022年春以後、協力関係にある米CSLベーリング子会社が米国で運営する血漿採取センターへの納入を始める。 認証を取得したのは ...

Rika devices are installed in more than 300 CSL Plasma centers to increase plasma supply for patients. It takes 1,200 plasma donations each year to treat an individual with severe hemophilia, just one ...

CSL says plasma donors can earn up to $100 per donation and as much as $750 per month. Here’s how it works and what to watch ...

With plasma collection as its stock-in-trade, the struggles of CSL during the coronavirus lockdown were understandable. But a rebound—fueled by a surge in post-pandemic collections and an $11.7 ...

Amid uncertainty for its vaccine division, CSL is growing the footprint of its bread-and-butter plasma therapies business by pledging a capital investment of about $1.5 billion for U.S.-based ...

Plasma, gathered mainly from paid donations in the US, is the raw ingredient needed to produce CSL’s suite of lifesaving products, including its immunoglobulins, conventional haemophilia treatment and ...

CSL's strategic transformation involves a 15% workforce reduction and closing 22 US plasma centers to enhance efficiency and simplify operations. The restructuring is expected to generate annual ...

Add articles to your saved list and come back to them any time. CSL boss Paul McKenzie is looking to make the company’s multi-billion dollar blood plasma business more efficient as the biotech tackles ...

CSL will outlay $1.5bn over the next five years in the US to grow its footprint of plasma therapy production, the latest pharma company to pour money into the country amid tariff threats.

CSL (ASX:CSL) has posted its half-year results, delivering results that are best described as mixed. At the headline level, ...

CSL Limited is one of the largest global biotechnology companies globally that specializes in the research, development, and manufacturing of plasma-based therapies, vaccines, and other pharmaceutical ...